Characterisation of heterozygous PMS2 variants in French patients with Lynch syndrome

被引:12
|
作者
Wang, Qing [1 ]
Leclerc, Julie [2 ,3 ]
Bougeard, Gaelle [4 ,5 ]
Olschwang, Sylviane [6 ]
Vasseur, Stephanie [4 ,5 ]
Cassinari, Kevin [4 ,5 ]
Boidin, Denis [7 ]
Lefol, Cedrick [1 ]
Naibo, Pierre [1 ]
Frebourg, Thierry [4 ,5 ]
Buisine, Marie Pierre [2 ,3 ]
Baert-Desurmont, Stephanie [4 ,5 ]
机构
[1] Ctr Leon Berard, Lab Constitut Genet Frequent Canc, HCL CLB, F-69008 Lyon, France
[2] Lille Univ, JPA Res Ctr, INSERM UMR S 1172, Lille, France
[3] Lille Univ Hosp, Dept Biochem & Mol Biol, Lille, France
[4] Rouen Univ Hosp, Dept Genet, Rouen, France
[5] Normandy Ctr Genom & Personalized Med, UNIROUEN, Rouen, France
[6] Aix Marseille Univ, Hop Europeen & Grp Ramsay Gen Sante, Hop Clairval, Dept Genet Med,INSERM GMGF UMR 1251, Marseille, France
[7] Lille Univ Hosp, Dept Biochem & Mol Biol, Lille, France
关键词
cancer predisposition; Lynch syndrome; germline variant; MMR deficiency; PMS2; MISMATCH REPAIR; MUTATIONS; GUIDELINES; HNPCC;
D O I
10.1136/jmedgenet-2019-106256
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Heterozygous germlinePMS2variants are responsible for about 5% of Lynch syndrome (LS) but their prevalence is most likely underestimated because of complicated routine screening caused by highly homologous pseudogenes. Consequently, there is limited knowledge on the implication of thePMS2gene in LS. Methods We report 200PMS2heterozygous variants identified in 195 French patients, including 112 unique variants classified as class-3/4/5. Results Genomic rearrangements account for 18% of alterations. The c.137G>T variant was observed in 18% of the patients, but a founder effect could not be clearly identified by haplotype analysis. Among class-4/5 variant carriers, the median age at first tumour onset was 49 years with a predominance of colorectal (80%) and endometrial (8.1%) cancers. Seven patients developed colorectal cancers before the age of 30 with the youngest at the age of 21. Only 6.2% of class-4/5 carriers had a family history fulfilling Amsterdam I/II criteria among patients with available data. Tumours fromPMS2variant carriers exhibited microsatellite instability (96%) and loss of PMS2 expression (76%), confirming the high predictive value of somatic analysis. Conclusion Our results provide further insight into the role of thePMS2gene in LS. WhilePMS2variants are mostly detected in families not fulfilling Amsterdam criteria, which supports their lower penetrance, they can nevertheless cause early-onset cancers, highlighting the variability of their penetrance.
引用
收藏
页码:487 / 499
页数:13
相关论文
共 50 条
  • [41] Germline mutation and protein expression analysis of mismatch repair genes MSH6 and PMS2 in Malaysian Lynch syndrome patients
    Zahary, Mohd Nizam
    Kaur, Gurjeet
    Abu Hassan, Muhammad Radzi
    Sidek, Ahmad Shanwani Mohd
    Singh, Harjinder
    Yeh, Lee Yeong
    Ankathil, Ravindran
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2014, 29 (02) : 261 - 262
  • [42] Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene
    Marina De Rosa
    Carlo Fasano
    Luigi Panariello
    Maria Scarano
    Giulio Belli
    Antonio Iannelli
    Fabio Ciciliano
    Paola Izzo
    Oncogene, 2000, 19 : 1719 - 1723
  • [43] Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene
    De Rosa, M
    Fasano, C
    Panariello, L
    Scarano, MI
    Belli, G
    Iannelli, A
    Ciciliano, F
    Izzo, P
    ONCOGENE, 2000, 19 (13) : 1719 - 1723
  • [44] Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome
    van der Klift, Heleen M.
    Mensenkamp, Arjen R.
    Drost, Mark
    Bik, Elsa C.
    Vos, Yvonne J.
    Gille, Hans J. J. P.
    Redeker, Bert E. J. W.
    Tiersma, Yvonne
    Zonneveld, Jose B. M.
    Garcia, Encarna Gomez
    Letteboer, Tom G. W.
    Olderode-Berends, Maran J. W.
    van Hest, Liselotte P.
    van Os, Theo A.
    Verhoef, Senno
    Wagner, Anja
    van Asperen, Christi J.
    ten Broeke, Sanne W.
    Hes, Frederik J.
    de Wind, Niels
    Nielsen, Maartje
    Devilee, Peter
    Ligtenberg, Marjolijn J. L.
    Wijnen, Juul T.
    Tops, Carli M. J.
    HUMAN MUTATION, 2016, 37 (11) : 1162 - 1179
  • [45] A PMS2 non-canonical splicing site variant leads to aberrant splicing in a patient suspected for lynch syndrome
    Ahmed Bouras
    Pierre Naibo
    Clémentine Legrand
    François Le Marc’hadour
    Eric Ruano
    Chloé Grand-Masson
    Cedrick Lefol
    Qing Wang
    Familial Cancer, 2023, 22 : 303 - 306
  • [46] Development and Validation of a Comprehensive Assay for Detection of PMS2 Gene Variants
    Butz, M. L.
    Peterson, L. M.
    Howe, S. C.
    Lundquist, P. A.
    Courteau, L. K.
    Thomas, B. C.
    Kipp, B. R.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 650 - 650
  • [47] Novel variants of unknown significance in the PMS2 gene identified in patients with hereditary colon cancer
    Liccardo, Raffaella
    Della Ragione, Carlo
    Mitilini, Nunzio
    De Rosa, Marina
    Izzo, Paola
    Duraturo, Francesca
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6719 - 6725
  • [48] A PMS2 non-canonical splicing site variant leads to aberrant splicing in a patient suspected for lynch syndrome
    Bouras, Ahmed
    Naibo, Pierre
    Legrand, Clementine
    Le Marc'hadour, Francois
    Ruano, Eric
    Grand-Masson, Chloe
    Lefol, Cedrick
    Wang, Qing
    FAMILIAL CANCER, 2023, 22 (03) : 303 - 306
  • [49] Ovarian uveal melanoma metastasis showing MLH1/PMS2 protein loss in a patient with Lynch Syndrome
    Lobo, J.
    Pinto, C.
    Freitas, M.
    Vieira, R.
    Machado, B.
    Pinheiro, M.
    Vizcaino, R.
    Oliva, E.
    Teixeira, M. R.
    Jeronimo, C.
    Bartosch, C.
    VIRCHOWS ARCHIV, 2016, 469 : S101 - S101
  • [50] Biallelic PMS2 mutations and a distinctive childhood cancer syndrome
    Tan, Tiong Yang
    Orme, Lisa M.
    Lynch, Elly
    Croxford, Matthew A.
    Dow, Christopher
    Dewan, Paddy A.
    Lipton, Lara
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2008, 30 (03) : 254 - 257